Recent performance context for Stoke Therapeutics

Stoke Therapeutics (STOK) has drawn fresh attention after recent trading left the stock at a last close of $31.61, with returns mixed across shorter and longer periods and a business still in the development stage.

Recent trading has been choppy, with a 7 day share price return of 6.54% but a 90 day share price return that is down 13.18%, set against a very large 1 year total shareholder return of 224.87% that points to strong momentum over the longer stretch.

If you are weighing Stoke Therapeutics against other opportunities in the sector, this could be a good moment to scan for 35 healthcare AI stocks as potential additions to your watchlist.

With Stoke Therapeutics still loss making and trading below analyst price targets, while also carrying a very large 1 year return, the key question is simple: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 8% Undervalued

Stoke Therapeutics last closed at $31.61, compared with a widely followed narrative fair value of $34.25. On that view, the stock is framed as modestly underpriced.

The shift toward disease-modifying therapies in severe epilepsies raises the regulatory and evidentiary bar. Any delay, additional data requirements, or failure to show clear differentiation versus emerging competitors could push out potential launch timing and limit peak revenue.

Want to see what justifies paying above today’s price? This narrative leans on ambitious revenue growth, changing margins and a rich future earnings multiple. See our AI narrative and valuation for Stoke Therapeutics.

Result: Fair Value of $34.25 (UNDERVALUED)

However, this depends on key risks, including the long Phase 3 EMPEROR trial failing to confirm earlier data, and the possibility that regulators may require more evidence before any potential approval.

Another View: What The P/B Ratio Suggests

While the narrative fair value points to modest undervaluation, the picture looks different when you look at Stoke Therapeutics through its P/B ratio. The stock trades at around 5x book value, compared with 2.7x for the broader US Biotechs industry, which implies investors are already paying a premium for each dollar of net assets.

That premium can reflect confidence in future growth, but it also raises the bar for what needs to go right on trials, partnerships, and eventual commercialization for today’s price to hold up. For a fuller sense of how this valuation gap could cut either way for you as a shareholder, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals like these can make sentiment tricky to read, so if you are interested, move quickly, review the data first hand, and weigh both the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If Stoke Therapeutics has you thinking more broadly about your portfolio, now is the moment to scan for other clear, data backed opportunities before they move away.

• Spot potential high return outliers early by reviewing 23 elite penny stocks with strong financials before crowd attention fully builds around them.
• Strengthen your core holdings with companies that look attractively priced on fundamentals by checking the 46 high quality undervalued stocks.
• Balance return potential with capital preservation by focusing on 64 resilient stocks with low risk scores that aim to keep volatility contained.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.